Antonio Aversa1, Simona Fittipaldi2, Davide Francomano3, Viviana M Bimonte4, Emanuela A Greco3,5, Clara Crescioli4, Luigi Di Luigi4, Andrea Lenzi3, Silvia Migliaccio4. 1. Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy. aversa@unicz.it. 2. IRCCS SDN, Napoli, Italy. 3. Department of Experimental Medicine, Section of Medical Pathophysiology, Endocrinology and Nutrition, "Sapienza" University of Rome, Rome, Italy. 4. Department of Movement, Human and Health Sciences, Section of Health Sciences, "Foro Italico" University of Rome, Rome, Italy. 5. LiSa Laboratory, Policlinico Catania, University of Catania, Catania, Italy.
Abstract
PURPOSE:Phosphodiesterase type-5 inhibitor administration in diabetic men with erectile dysfunction (ED) is associated with reduced waist circumference. We evaluated potential effects of daily tadalafil administration on body composition and investigated its possible mechanism(s) of action in C2C12 skeletal muscle cells in vitro. METHODS:Forty-three men on stable caloric intake (mean age 48.5 ± 7; BMI 25.5 ± 0.9 kg/m2) complaining mild ED and/or low urinary tract symptoms (LUTS) were randomly assigned to receive tadalafil (TAD) 5 mg/daily (once-a-day=OAD-TAD; n = 23) or 20 mg on-demand (on-demand=OD-TAD; n = 20) for 2 months. Primary outcomes were variations of body composition measured by Dual-energy X-ray absorptiometry; secondary outcomes were ED/LUTS questionnaire scores along with hormone (testosterone, estradiol, insulin) and endothelial function (Endopat2000) variations. RESULTS: OAD-TAD increased abdominal lean mass (p < 0.01) that returned to baseline after 2 months withdrawal. LUTS scores improved (p<0.01) in OD-TAD while ED scores improved (p < 0.01) in both groups. We found significant improvements in endothelial function (p < 0.05) that directly correlated with serum insulin (p < 0.01; r = 0.3641) and inversely correlated with estradiol levels (p < 0.01; r = 0.3655) even when corrected for potential confounders. Exposure of C2C12 cells upon increasing tadalafil concentrations (10-7 to 10-6 M) increased total androgen receptor mRNA and protein expression as well as myogenin protein expression after 24 and 72 h (2.8 ± 0.4-fold and 1.4 ± 0.02-fold vs. control, respectively, p < 0.05). CONCLUSIONS: Daily tadalafil improved lean mass content in non-obese men probably via enhanced insulin secretion, estradiol reduction, and improvement of endothelial function in vivo. The in vitro increased myogenin and androgen receptor protein expression in skeletal muscle cells suggests a translational action of phosphodiesterase type-5 on this receptor.
RCT Entities:
PURPOSE: Phosphodiesterase type-5 inhibitor administration in diabeticmen with erectile dysfunction (ED) is associated with reduced waist circumference. We evaluated potential effects of daily tadalafil administration on body composition and investigated its possible mechanism(s) of action in C2C12 skeletal muscle cells in vitro. METHODS: Forty-three men on stable caloric intake (mean age 48.5 ± 7; BMI 25.5 ± 0.9 kg/m2) complaining mild ED and/or low urinary tract symptoms (LUTS) were randomly assigned to receive tadalafil (TAD) 5 mg/daily (once-a-day=OAD-TAD; n = 23) or 20 mg on-demand (on-demand=OD-TAD; n = 20) for 2 months. Primary outcomes were variations of body composition measured by Dual-energy X-ray absorptiometry; secondary outcomes were ED/LUTS questionnaire scores along with hormone (testosterone, estradiol, insulin) and endothelial function (Endopat2000) variations. RESULTS: OAD-TAD increased abdominal lean mass (p < 0.01) that returned to baseline after 2 months withdrawal. LUTS scores improved (p<0.01) in OD-TAD while ED scores improved (p < 0.01) in both groups. We found significant improvements in endothelial function (p < 0.05) that directly correlated with serum insulin (p < 0.01; r = 0.3641) and inversely correlated with estradiol levels (p < 0.01; r = 0.3655) even when corrected for potential confounders. Exposure of C2C12 cells upon increasing tadalafil concentrations (10-7 to 10-6 M) increased total androgen receptor mRNA and protein expression as well as myogenin protein expression after 24 and 72 h (2.8 ± 0.4-fold and 1.4 ± 0.02-fold vs. control, respectively, p < 0.05). CONCLUSIONS: Daily tadalafil improved lean mass content in non-obesemen probably via enhanced insulin secretion, estradiol reduction, and improvement of endothelial function in vivo. The in vitro increased myogenin and androgen receptor protein expression in skeletal muscle cells suggests a translational action of phosphodiesterase type-5 on this receptor.
Authors: Julio E Ayala; Deanna P Bracy; Brianna M Julien; Jeffrey N Rottman; Patrick T Fueger; David H Wasserman Journal: Diabetes Date: 2007-01-17 Impact factor: 9.461
Authors: Emanuela A Greco; Marcello Pili; Roberto Bruzziches; Giovanni Corona; Giovanni Spera; Antonio Aversa Journal: J Sex Med Date: 2006-07 Impact factor: 3.802
Authors: H Duplain; R Burcelin; C Sartori; S Cook; M Egli; M Lepori; P Vollenweider; T Pedrazzini; P Nicod; B Thorens; U Scherrer Journal: Circulation Date: 2001-07-17 Impact factor: 29.690
Authors: L Di Luigi; C Baldari; F Pigozzi; G P Emerenziani; M C Gallotta; F Iellamo; E Ciminelli; P Sgrò; F Romanelli; A Lenzi; L Guidetti Journal: Int J Sports Med Date: 2007-07-05 Impact factor: 3.118
Authors: Giuseppe Defeudis; Rossella Mazzilli; Marta Tenuta; Giovanni Rossini; Virginia Zamponi; Soraya Olana; Antongiulio Faggiano; Paolo Pozzilli; Andrea M Isidori; Daniele Gianfrilli Journal: Diabetes Metab Res Rev Date: 2021-09-21 Impact factor: 8.128
Authors: Emanuela Alessandra Greco; Cristina Antinozzi; Luigi Di Luigi; Antonio Aversa; Paolo Sgrò Journal: Int J Mol Sci Date: 2022-04-11 Impact factor: 6.208
Authors: Viviana M Bimonte; Francesco Marampon; Ambra Antonioni; Simona Fittipaldi; Elisabetta Ferretti; Richard G Pestell; Mariaignazia Curreli; Andrea Lenzi; Giovanni Vitale; Antonio Brunetti; Silvia Migliaccio; Antonio Aversa Journal: Int J Mol Sci Date: 2021-01-13 Impact factor: 5.923